BDSX vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe fundamental deterioration. Despite strong revenue growth and a bullish analyst recommendation, persistent unprofitability, negative valuation multiples, and bearish insider activity raise substantial concerns. The stock's recent sharp price rebound contrasts with a 5-year return of -97.8%, reflecting extreme volatility and lack of long-term value creation. While gross margins are healthy at 79.82%, the negative ROE of -302.55% and negative price-to-book ratio highlight structural profitability and equity issues.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BDSX vs JNJ: Head-to-Head Comparison
This page compares Biodesix, Inc. (BDSX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.